Background
Phase III, double-blind, placebo-controlled RCT. 614 patients with NDMM aged ≤65 who achieved at least partial response after single ASCT (high-dose melphalan 200mg/m²). Randomized to lenalidomide consolidation (2 cycles) followed by lenalidomide maintenance vs placebo consolidation + placebo maintenance. Concurrent with CALGB 100104, established lenalidomide's post-ASCT role in the European context.
Interventions and follow up
Arm A: Lenalidomide consolidation 25mg PO days 1–21 q28d × 2 cycles (post-ASCT, day +30), then maintenance 10–15mg PO days 1–21 q28d until progression
Arm B: Placebo consolidation × 2 cycles, then placebo maintenance until progression (crossover to open-label lenalidomide at progression allowed)
Primary endpoint: Progression-free survival
Median follow up: 45 months
Arm B: Placebo consolidation × 2 cycles, then placebo maintenance until progression (crossover to open-label lenalidomide at progression allowed)
Primary endpoint: Progression-free survival
Median follow up: 45 months
Results
Median PFS (primary): 41 months (lenalidomide) vs 23 months (placebo) — HR 0.50, P<.001
4-year PFS: 43% vs 22%
OS: No significant difference at primary analysis (crossover confounded)
MRD negativity post-consolidation: Higher in lenalidomide arm
4-year PFS: 43% vs 22%
OS: No significant difference at primary analysis (crossover confounded)
MRD negativity post-consolidation: Higher in lenalidomide arm
Adverse events
Hematologic (grade ≥3): Neutropenia 49% (lenalidomide) vs 15% (placebo); thrombocytopenia 12% vs 3%
Constitutional (grade ≥3): Fatigue 6% vs 2%; no excess cardiovascular events
Second primary malignancies: 3.1-fold higher risk with lenalidomide (HR 3.1, P<.001) — predominantly hematologic
Constitutional (grade ≥3): Fatigue 6% vs 2%; no excess cardiovascular events
Second primary malignancies: 3.1-fold higher risk with lenalidomide (HR 3.1, P<.001) — predominantly hematologic
Conclusions
Lenalidomide consolidation + maintenance significantly doubled PFS vs placebo post-ASCT in NDMM (41 vs 23 months), with no OS benefit at primary analysis due to crossover. The 3.1-fold SPM risk is the primary safety concern requiring consent and monitoring. With CALGB 100104, formed the basis for FDA approval.
Key Limitations
Higher SPM risk (3.1-fold vs placebo) exceeds CALGB 100104 (2.6-fold). No OS benefit at primary analysis, unlike CALGB 100104 long-term follow-up; may reflect crossover timing. The consolidation component (2 cycles high-dose lenalidomide) is not standard at most North American centers, which prefer direct lower-dose maintenance. Optimal duration unknown.
Clinical Context
IFM 2005-02 was the French companion to CALGB 100104, together forming the evidence base for lenalidomide post-ASCT maintenance as an ESMO standard recommendation. The SPM risk informs shared decision-making. Newer maintenance approaches (daratumumab in AURIGA) and MRD-guided discontinuation (MIDAS) may allow cessation in deep responders.